MedTrace Logo

Topical Cetirizine in Treatment of Localized Alopecia Areata

NCT05803070 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2023-04-07

No results posted yet for this study

Summary

Evaluate and compare the efficacy and safety of topical cetirizine 1%, versus topical betamethasone valerate 0.1% in the treatment of localized alopecia areata.

Conditions

Interventions

DRUG

Topical Cetirizine 1 %

topical cetirizine belongs to anti histamines group

DRUG

Topical betamethasone valerate 0.1%

topical betamethasone valerate belongs to corticosteroids group

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-09-01
Completion
2024-10-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05803070 on ClinicalTrials.gov